Filings · News reference

Cue Biopharma Files Prospectus For Resale Of 1,505,570 Shares, Including 87,500 Underlying Pre-Funded Warrants, Issued In $50M July Private Placement

Aug 12, 2026, 8:52 PMBenzinga Newsdesk

https://www.sec.gov/Archives/edgar/data/1645460/000119312526346867/d136967ds3.htm

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 14, 2026, 8:27 PMBenzinga Newsdesk
Cue Biopharma Q2 EPS $(24.14) Misses $(1.69) Estimate, Sales $7.877M Beat $3.000M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(24.14) per share which missed the analyst consensus estimate of $(1.69) by 1328.4 percent. This is a 794.07 percent decrease over losses of $(2.70) per share
CUE
SEC EDGARAug 14, 2026, 8:00 PMSEC EDGAR
8-K filing — Cue Biopharma, Inc. (CUE)
Filed: 2026-08-14 AccNo: 0001193125-26-352126 Size: 413 KB Item 2.02: Results of Operations and Financial Condition
CUE
BenzingaAug 3, 2026, 12:33 PMBenzinga Newsdesk
Cue Biopharma Appoints James M. Ahlers CFO
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial
CUE